Device Tissue Diagnostics

Benchmark Ultra

Payments companies reported to CMS as associated with Benchmark Ultra. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$16Kassociated payments (2023-2025)
154clinicians with associated payments
3companies reporting

By year

2023 $2,661
2024 $4,940
2025 $8,160

Payments reported as associated with Benchmark Ultra, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Anatomic Pathology & Clinical Pathology $7,216
Clinical Pathology/Laboratory Medicine $3,761
Dermatopathology (Pathology) $3,754
Anatomic Pathology $373
Medical Oncology $267
Hematology (Pathology) $114

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Benchmark Ultra

These are the largest totals companies reported as associated with Benchmark Ultra. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Drazen Jukic Savannah, GA Dermatopathology (Pathology) $3,086.69
Magdalena Czader Indianapolis, IN Clinical Pathology/Laboratory Medicine $2,258.17
Michael Feldman Indianapolis, IN Anatomic Pathology & Clinical Pathology $1,703.49
Chirag Patel Scottsdale, AZ Clinical Pathology/Laboratory Medicine $1,388.42
Elba Torres Matundan San Juan, PR Anatomic Pathology & Clinical Pathology $1,055.47
Rosa Cortes Rivera San Juan, PR Anatomic Pathology & Clinical Pathology $830.73
Kelly Hall Fort Sam Houston, TX Dermatopathology (Pathology) $474.14
Nathan Teschan San Antonio, TX Anatomic Pathology & Clinical Pathology $460.03
Yorke Young Knoxville, TN Anatomic Pathology & Clinical Pathology $329.91
Frank Sinicrope Rochester, MN Medical Oncology $267.21

Prescribed Benchmark Ultra?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.